175 related articles for article (PubMed ID: 1678995)
1. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.
Oudard S; Thierry A; Jorgensen TJ; Rahman A
Cancer Chemother Pharmacol; 1991; 28(4):259-65. PubMed ID: 1678995
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.
Sela S; Husain SR; Pearson JW; Longo DL; Rahman A
J Natl Cancer Inst; 1995 Jan; 87(2):123-8. PubMed ID: 7707383
[TBL] [Abstract][Full Text] [Related]
3. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
Rahman A; Husain SR; Siddiqui J; Verma M; Agresti M; Center M; Safa AR; Glazer RI
J Natl Cancer Inst; 1992 Dec; 84(24):1909-15. PubMed ID: 1361008
[TBL] [Abstract][Full Text] [Related]
4. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.
Thierry AR; Jorgensen TJ; Forst D; Belli JA; Dritschilo A; Rahman A
Cancer Commun; 1989; 1(5):311-6. PubMed ID: 2577154
[TBL] [Abstract][Full Text] [Related]
5. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.
Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A
FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
Perez-Soler R; Ling YH; Zou Y; Priebe W
Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin.
Sadasivan R; Morgan R; Fabian C; Stephens R
Cancer Lett; 1991 May; 57(2):165-71. PubMed ID: 1673873
[TBL] [Abstract][Full Text] [Related]
8. The influence of Na+,K(+)-pump blockade on doxorubicin-mediated cytotoxicity and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA
Cancer Chemother Pharmacol; 1990; 26(3):163-7. PubMed ID: 2162743
[TBL] [Abstract][Full Text] [Related]
9. Effect of liposomes on P-glycoprotein function in multidrug resistant cells.
Thierry AR; Dritschilo A; Rahman A
Biochem Biophys Res Commun; 1992 Sep; 187(2):1098-105. PubMed ID: 1356335
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.
Lai GM; Chen YN; Mickley LA; Fojo AT; Bates SE
Int J Cancer; 1991 Nov; 49(5):696-703. PubMed ID: 1682280
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
13. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.
Lai GM; Moscow JA; Alvarez MG; Fojo AT; Bates SE
Int J Cancer; 1991 Nov; 49(5):688-95. PubMed ID: 1682279
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
15. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
16. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
[TBL] [Abstract][Full Text] [Related]
17. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
[TBL] [Abstract][Full Text] [Related]
18. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells.
Hu YP; Henry-Toulmé N; Robert J
Eur J Cancer; 1995; 31A(3):389-94. PubMed ID: 7786607
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes.
Fan D; Bucana CD; O'Brian CA; Zwelling LA; Seid C; Fidler IJ
Cancer Res; 1990 Jun; 50(12):3619-26. PubMed ID: 2340511
[TBL] [Abstract][Full Text] [Related]
20. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
